Survey
Quarterly Survey: Colon Cancer Screening and Exact Sciences' Cologuard April 2024
Ticker(s): EXASThe survey includes 20 Gastrologists with practice in colorectal cancer screening.
What is the average number of patients you oversee per month who undergo colorectal cancer screening tests?
How many patients have you recommended Cologuard as a screening tool for colorectal cancer in the past 30 days?
How many patients do you expect to recommend Cologuard as a screening tool for colorectal cancer in the next 30 days?
What percentage (%) of your patients seeking a non-invasive colorectal cancer screening test(s) did you recommend the following test(s) 1 year ago?
- Fecal immunochemical test (FIT):
- Stool DNA test (such as Cologuard):
- CT colonography (virtual colonoscopy):
- Flexible sigmoidoscopy:
- Blood-based test:
- Other:
What percentage (%) of your patients seeking a non-invasive colorectal cancer screening test(s) do you recommend the following test(s) in your practice today?
- Fecal immunochemical test (FIT):
- Stool DNA test (such as Cologuard):
- CT colonography (virtual colonoscopy):
- Flexible sigmoidoscopy:
- Blood-based test:
- Other:
What percentage % of your patients seeking a non-invasive colorectal cancer screening test(s) do you anticipate recommending the following test(s) in 1 year?
- Fecal immunochemical test (FIT):
- Stool DNA test (such as Cologuard):
- CT colonography (virtual colonoscopy):
- Flexible sigmoidoscopy:
- Blood-based test:
- Other:
How would you rate Cologuard on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
How would you rate fecal immunochemical tests (FIT) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
Do you think Cologuard has the potential to increase the number of patients who get screened for colorectal cancer?
Why or why not?
To what extent do you estimate Cologuard will increase (%) the colorectal cancer screening market in the next year?
Please elaborate on your view of Cologuard.
What changes, if any, have you noticed with payor reimbursement and insurance for non-invasive colorectal cancer screening tests?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Cologuard as a screening tool for colorectal cancer?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
